E815
TEAS SECTION 8 & 15 RECEIVED
06/09/2026
Back to search
Official data from USPTO
UBRELVY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
06/10/2026
Trademark type
Combined
Nice classes
5
Filing date
11/07/2018
Registration date
06/09/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/09/2020
Last transaction
06/10/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
01/22/2020
First use in commerce
01/22/2020
Drawing code
3
Owner type
99
Owner location
Dublin 17, IE
Examiner
FATHY, DOMINIC
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "UBRELVY" below two wavy lines, both of which generally begin above the "E" in "UBRELVY" and extend in opposite directions.
Holders and representatives
Holders
Allergan Pharmaceuticals International Limited
Allergan Pharmaceuticals International Limited
Representatives
Matthew O. Brady
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations used in connection with anti-agingfor use in the treatment of glabellar linesfacial wrinklesasymmetries and defects and conditions of the human skinfor facial aesthetic surgeryfacial aesthetic reconstructionbreast aesthetic treatment procedures; topical antibioticsanti-inflammatoryanti-infectiveanti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutionsartificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disordersmuscle dystoniasmooth muscle disordersautonomic nerve disordersheadacheshyperhidrosissports injuriescerebral palsyspasmstremors and pain; dermatological formulationsmedicated dry skin lotions and creamsacne medications and medicated skin lightener lotions and creams; Oraltransdermalinjectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that supportencourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's diseasedementiaAIDS-related dementiaCNSneurological disordersneurodegenerative disordersdepression; neuroprotective agent; antidepressants; pharmaceuticalsantipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin caremedicated skin cleanserstonersmoisturizersrejuvenatorsrehydrating creamslotions for the face and body
Publications
History of USPTO decisions and trademark events.
22 publications found
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/09/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
06/09/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/02/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/01/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/20/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/20/2020
IUAF
USE AMENDMENT FILED
04/06/2020
EISU
TEAS STATEMENT OF USE RECEIVED
04/06/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
10/30/2019
EX1G
SOU EXTENSION 1 GRANTED
10/28/2019
EXT1
SOU EXTENSION 1 FILED
10/28/2019
EEXT
SOU TEAS EXTENSION RECEIVED
10/28/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/30/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/05/2019
PUBO
PUBLISHED FOR OPPOSITION
03/05/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/13/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/25/2019
DOCK
ASSIGNED TO EXAMINER
01/24/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
11/27/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/24/2018
NWAP
NEW APPLICATION ENTERED
11/10/2018
Continuous trademark protection
Get notified about every new filing that threatens UBRELVY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.